The Rise Of Data Exchanges - New Eckerson Group Report Confirms Data Exchange As Organizations’ Next Step Into The Data Economy
Dawex, the leading data exchange technology company, is featured in Eckerson Group’s latest report on “The Rise of Data Exchanges - Frictionless Integration of Third-Party Data”. The global research firm specialized in data analytics shared its insights on how data exchange technology helps organizations eliminate “the friction from finding, acquiring and integrating data” by facilitating data circulation and data commercialization.
Dawex Data Exchange technology covers the full range of data exchanges modes. In this report, Eckerson offers an overview of data exchange, its benefits, and presents the challenges of implementing a data exchange strategy. It defines the relationship and engagement between data providers and acquirers as relying on three types of exchanges: peer-to-peer data exchange, private data exchange and data marketplace. According to the report ideally a data exchange supports all three modes.
Dawex Data Exchange technology is one of the only companies addressing the full scope of models and delivers sophisticated features allowing public and private organizations to orchestrate data circulation, source, distribute and exchange data securely, in compliance with regulations.
“Data exchanges are emerging as a key component of the data economy” states Wayne Eckerson, President, Eckerson Group. “Connecting data providers and acquirers through a seamless experience, data exchanges are creating a modern-day gold rush to help modern, digital organizations address their insatiable hunger for data. Companies need to understand the new dynamics and prepare accordingly.”
The World Economic Forum set an important milestone in June 2020 by awarding Dawex the title of “Technology Pioneer" and naming it for the Global Future Council on Data Policy. In doing so, it acknowledges the important role that data exchange plays for the data economy. This report is yet another recognition that data exchanges and data marketplaces are key business enablers for data hungry organizations.
“We are excited to observe that the role of data exchange is increasingly understood by the market and market observers” says Laurent Lafaye, Dawex co-CEO. “Even more importantly the appreciation of data marketplaces and data exchange standards as expressed in the Eckerson report reflect the high level of requirements we have set for Dawex.”
“Data exchange and data marketplaces are now clearly top of the agenda of an increasing number of corporations, public institutions and governments around the world. It is inspiring to see data exchange initiatives and frameworks multiplying everywhere: from the World Economic Forum data policy workgroup, to the Data Exchange Association (DXA) and the Japan Data Exchange (JDEX). Dawex anticipated these trends, which now call for a more standardized definition of data transaction intermediaries. The Eckerson report’s well-articulated view of what data exchange is and what is at stake, contributes directly to this important conversation.” concludes Fabrice Tocco, Dawex co-CEO.
Download Eckerson report.
About Dawex
Dawex, the leading data exchange technology company and the operator of the largest data marketplace, allows organizations to orchestrate data circulation, by sourcing and exchanging data securely, and in full compliance with regulations. Today 12,000+ organizations from 20+ sectors rely on Dawex Global Data Marketplace and Data Exchange Platform solutions to build their data exchange strategy. In 2020, Dawex is named Technology Pioneer by the World Economic Forum. Created in 2015, Dawex is a French company with offices in Paris, Lyon and Montreal, expanding business operations to Asia and the Middle East. www.dawex.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201112005769/en/
Contact information
Dawex press contact
Charles Parant
charles.parant@dawex.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Q4 Helps Public Companies and Investment Firms Keep Their Teams Aligned and Informed28.7.2021 16:00:00 EEST | Press release
Q4 Inc. announced today it is applying its unique expertise in delivering mission-critical virtual events to help public companies, buy-side and sell-side firms build transparency, trust and excitement across a widely dispersed workforce. With the seismic shift in working models giving employees increasing flexibility to work both in remote or hybrid setups, maintaining a strong internal communications platform to globally distributed teams is vital for companies across all industries. Simultaneously, the commitment to providing a sustainable work environment and strong corporate culture continues to intensify as companies seek to implement successful ESG policies and programs. Q4’s new Corporate Town Hall subscriptions combine technology and a premium end-to-end service model to help its capital markets clients communicate strategy and best practices, provide quarterly business reviews, host sales kick-offs, and ultimately foster the inclusive culture they have worked so hard to devel
ZS Elects Pratap Khedkar to CEO28.7.2021 16:00:00 EEST | Press release
Global professional services firm ZS today announced that Pratap Khedkar, head of the firm’s global biopharmaceuticals and healthcare ecosystem practices, has been elected to CEO by the firm’s leaders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210728005232/en/ Pratap Khedkar, CEO, ZS (Photo: Business Wire) Khedkar is the third CEO in ZS’s nearly 40-year history. He was elected by his peers, a structure ZS’s founders Andris A. Zoltners and Prabhakant Sinha established to ensure cultural continuity and to elevate leaders who embody the company’s dedication to strategy, innovation and client collaboration. He succeeds Chris Wright, who served the firm’s maximum term and will be affiliated with ZS for the next five years as part of its principal emeritus program, focusing on the projects that he’s most passionate about. Khedkar has held various leadership roles during his 21 years with ZS. Khedkar has led the firm’s global
Dixa, the Next-Gen CX Platform, Raises $105M Series C to Transform Customer Service Worldwide28.7.2021 15:30:00 EEST | Press release
Founded as a customer service solution that evolved into a customer engagement platform, European company Dixa today announced a Series C funding round totaling $105M. The company is leading the change from customer service to value creation with a multiexperience approach, challenging the status quo and delivering value-driven experiences that generate results for businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210728005430/en/ Dixa Founding Team (Photo: Business Wire) The Series C round is led by General Atlantic, a leading global growth equity investor with a history of backing and scaling companies that transformed their industries, with participation from existing investors Notion Capital Project A and Seed Capital. Dixa will leverage the new funds to invest in product development, including potential new acquisitions (following Dixa’s acquisition of Melbourne-based Elevio in January 2021), and plans to quadr
V.E, Part of Moody’s ESG Solutions, Provides Second Party Opinion on the Kingdom of Spain’s Sovereign Green Bond Framework28.7.2021 15:30:00 EEST | Press release
Moody’s ESG Solutions Group announced today that V.E has provided a Second Party Opinion (SPO) on the Kingdom of Spain’s Sovereign Green Bond Framework. The Framework is aligned with the four core components of the Green Bond Principles 2021 and follows best market practices identified by V.E. Net proceeds of the bonds will exclusively be used to finance or refinance projects tied to the country’s environmental objectives, including renewable energy, biodiversity protection, and climate change adaptation. “The bonds issued under Spain’s Framework will provide an ‘advanced’ contribution to sustainability, the highest score on our four-point scale,” said Patrick Mispagel, MD – Sustainable Finance at Moody’s ESG Solutions. “Our assessment reflects that in many cases Spain’s Framework followed the detailed technical eligibility criteria of the EU Taxonomy Climate Delegated Act. We expect to see additional sovereign issuances as nations increasingly seek to raise capital to support climate
U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Takeda’s Investigational Compound, TAK-994, an Oral Orexin Agonist in Clinical Development for Narcolepsy Type 1 (NT1)28.7.2021 15:15:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to TAK-994,1 its Phase 2 investigational oral orexin agonist, which is designed to selectively target orexin 2 receptors. TAK-994 is currently being studied for the treatment of excessive daytime sleepiness (EDS) in patients with narcolepsy type 1 (NT1),2 a chronic neurological disorder that alters the sleep-wake cycle.3 EDS is a hallmark symptom of NT1 and is characterized by a person’s inability to stay awake and alert throughout the day, and falling asleep unintentionally or at inappropriate times on a daily basis.3,4 The FDA’s Breakthrough Therapy Designation process is designed to expedite the development and review of a drug that is intended to treat a serious condition, for which preliminary clinical evidence exists indicating it may demonstrate a substantial improvement over available therapies on at
BlueConic is the First Customer Data Platform to Offer a Data Clean Room Solution28.7.2021 15:02:00 EEST | Press release
Driven by the death of the third-party cookie and its debilitating impact on the digital advertising industry, data clean rooms are growing in popularity among brands and publishers alike. To meet this demand, BlueConic is proud to announce its own comprehensive data clean room solution, making it the first customer data platform (CDP) to do so. The move will enable its customer base of over 300 companies worldwide to facilitate second-party data sharing in a privacy-safe environment. The solution provides brands and publishers with a privacy-compliant way to combat the effects of Apple and Google’s decisions to deprecate the use of third-party cookies in their respective web browsers, Safari and Chrome. Without such a solution, marketers will lose the ability to measure the impact of digital advertising spend once and for all. Industry analysts agree that BlueConic is uniquely poised to offer such a solution. Unlike other data clean rooms on the market, BlueConic’s solution will: Insu
Vertex to Initiate Phase 3 Development Program for New Once-Daily Triple Combination Regimen in People With Cystic Fibrosis28.7.2021 15:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the company will initiate a Phase 3 development program for the new once-daily investigational triple combination of VX-121/tezacaftor/VX-561 (deutivacaftor) in the second half of 2021. The combination of VX-121/tezacaftor/VX-561 was first identified as having potential for increased efficacy based on its ability to drive higher levels of chloride transport compared to TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in human bronchial epithelial cells in vitro. The combination of VX-121/tezacaftor/VX-561 was evaluated in a Phase 2 study in people with cystic fibrosis (CF) ages 18 and older with one F508del mutation and one minimal function mutation (F/MF) and in people with CF ages 18 and older with two F508del mutations (F/F). The regimen was generally well-tolerated, and the study met the primary efficacy endpoint of absolute change from baseline in ppFEV1 and all secondary efficacy endpoints including abso
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom